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Abstract. Low-dose and long-term administration of 14-
membered macrolide antibiotics is well-known to be effective
in the treatment of chronic airway diseases. Although there is
much evidence that the anti-inflammatory action, but not the
anti-microbial action of macrolides, is responsible for the
clinical efficacy of these agents on chronic airway
inflammatory diseases, the precise therapeutic mechanisms
are not well-understood. Since thioredoxin (TRX) has now
attracted attention as an endogenous peptide with
immunomodulatory effects, the present study was undertaken
to examine whether macrolide antibiotics could favorably
modulate the clinical status of such diseases via the
production of TRX from nasal epithelial cells in vitro. Nasal
epithelial cells (5×105 cells/ml) obtained from five patients
were stimulated with 50 μM H2O2 in the presence of different
concentrations of macrolide antibiotics for 24 h. TRX levels
in culture supernatants were examined by enzyme-linked
immunosorbent assay. We also examined the influence of
macrolide antibiotics on TRX mRNA expression and mRNA
translation by RT-PCR and a wheat germ cell-free protein
synthesis technique, respectively. The addition of
clarithromycin (CAM) to cell cultures caused an increase in
the ability of cells to produce TRX in response to H2O2
stimulation, and the minimum concentration that caused a
significant increase was 0.5 μg/ml. On the other hand,
josamycin, a 16-membered macrolide antibiotic, did not
increase TRX production induced by H2O2 stimulation.
Although the treatment of cells with CAM inhibits TRX
mRNA transcription, the agent might increase translation of
mRNA to produce specific proteins. The ability of CAM to
increase TRX production may account, at least in part, for
the clinical efficacy of this agent on chronic airway
inflammatory diseases, including chronic rhinosinositis. 
Macrolide antibiotics are a group of anti-bacterial agents
with a distinctive macrocyclic lactone ring combined with
sugars and are active against many species of Gram-positive
and some Gram-negative bacteria. It is now known that in
addition to anti-bacterial activity, these compounds exert
anti-inflammatory effects in vitro and in vivo through their
inhibitory action on inflammatory cell migration and
inflammatory cytokine production, amongst others (1-3). In
addition, macrolide antibiotics, especially 14-membered
macrolides, are well-known to have beneficial effects in the
treatment of chronic airway inflammatory diseases, such as
diffuse panbronchiolitis (DPB), chronic sinusitis (CS) and
cystic fibrosis (CF) (4). In this regard, much effort has been
made to elucidate the therapeutic mechanisms of macrolides
and revealed that the anti-inflammatory action, but not the
anti-microbial action of macrolides is responsible for the
clinical efficacy of the agents against chronic airway
inflammatory diseases (1-6). 
It is now accepted that inflammatory cells such as
neutrophils, which are the most important effector cells in
the development of chronic airway diseases, produced not
only several types of chemical mediators but also free
radicals, including O2
 –
and H2O2 (3, 4). Although
physiological production of free radicals is generally
believed to be essential in host defense, overproduction of
free radicals and their metabolites are harmful and cause
oxidative stress responses, which are implicated in the
pathogenesis of conditions such as DPB, CS and pulmonary
fibrosis (3, 7). On the other hand, under normal physiological
conditions, there are several types of antioxidants such as
glutathione, superoxide dismutase and hydrogen peroxide,
which prevent the development of oxidative stress responses.
Among these, thioredoxin (TRX) has attracted attention as
an endogenous antioxidant protein. TRX, which was
originally identified as a hydrogen donor for ribonucleotide
reductase in Escherichia coli, is a 12-kDa protein with two
redox active half-cysteine residues (-Cys-Gly-Pro-Cys-) (8-
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10). In addition to its anti-oxidative activity, TRX is reported
to exert immunomodulatory effects. Administration of
exogenous TRX suppresses airway hyper-responsiveness
induced by specific allergen challenge through the inhibition
of eosinophil accumulation in airways of mouse models of
asthma (11, 12). TRX also suppresses the chemotactic
response of neutrophils and monocytes induced by
stimulation with either lipopolysaccharide or monocyte
chemoattractant protein-1 (MCP-1) (13, 14). Moreover, TRX
is able to inhibit activity of purified human neutrophil
elastase as well as elastolytic activity of sputum prepared
from patients with CF (15). Since it is believed that elastase
plays an important role in the development of structural lung
damage, such as bronchiectasis, progressive pulmonary
function decline, and early death, which are observed in CF
and DPB (15, 16), the manipulation of the TRX system
consisting of TRX, TRX reductase and NADPH, may be
good targets in the treatment of chronic airway inflammatory
diseases, including CF and DPB. However, the influence of
macrolide antibiotics on the function of the TRX system is
not clear at present. In the present study, therefore, we
investigated the influence of macrolide antibiotics on the
TRX system by examining the effect of agents on TRX
production from human nasal epithelial cells in vitro. 
Materials and Methods
Reagents. Clarithromycin (CAM) was kindly donated by Taisho-
Toyama Pharmaceutical Co. Ltd. (Tokyo, Japan) as a preservative-
free pure powder. The agent was dissolved firstly in 100% ethyl
alcohol to a concentration of 10.0 mg/ml and then diluted with
phosphate buffered saline (PBS) to a concentration of 10 μg/ml.
This was sterilized by passing it through 0.2-μm filters, and stored
at 4˚C until used. Josamycin (JM) purchased from Sigma Pure
Chemical Co. (St Louis, MO, USA) was also dissolved in PBS in a
similar manner. 
Cell source and epithelial cell culture. Nasal polyp specimens were
surgically-obtained from patients with CS who had not received
any medical treatment, including systemic and topical steroid
application or oral macrolide antibiotics. Specimens were washed
five times with PBS that contained 500 μg/ml streptomycin, 500 U
penicillin and 5 μg/ml ampotericin B. These tissues were then
treated with 0.1% protease type XIV for 12 h at 4˚C. Epithelial cell
layers were then obtained and vigorously mixed with a pipette to
obtain a single-cell suspension. The cells were suspended in SABM
medium (Lonza Co., Ltd., Walkersville, MD, USA) at a density of
5×103 cells/ml. The cell suspension was introduced into triplicate
24-well tissue culture plates coated with human type I collagen and
cultured for 48 h, when the number of cells had reached
approximately 5 x 105 cells/well. The cells were then stimulated
with 50 μM H2O2 in the presence of different concentrations of
either CAM or JM. After 24 h, culture supernatants were collected
and stored at –40˚C until used. In the case of examination for
mRNA expression, cells were cultured in a similar manner for 12 h.
In all experiments, treatment of cells with the agents was started 
2 h before H2O2 stimulation.
Assay for TRX mRNA expression. Poly A+ mRNA was separated
from cultured cells with oligo(dT)-coated magnetic micro beads
(Milteny Biotec, Bergisch Gladbach, Germany). The first-strand
cDNA was synthesized from 1.0 μg of Poly A+ mRNA using a
Superscript cDNA synthesis kit (Invitrogen Corp., Carlsbad, CA,
USA) according to the manufacturer’s instructions. Polymerase
chain reaction (PCR) was then carried out using a GeneAmp 5700
Sequence Detection System (Applied Biosystems, Foster City, CA,
USA). The PCR mixture consisted of 2.0 μl of sample cDNA
solution (100 ng/μl), 25.0 μl of SYBR-Green Mastermix (Applied
Biosystems), 0.3 μl of both sense and anti-sense primers, and
distilled water to a final volume of 50.0 μl. The reaction was
conducted as follows: 4 min at 94˚C, followed by 40 cycles of 15 s
at 95˚C and 60 s at 60˚C. Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) was amplified as an internal control.
mRNA levels were calculated by using the comparative parameter
threshold cycle and normalized to GAPDH. The primers used for
real-time RT-PCR were 5’-GCCTTGCAAAATGATTCAAGC-3’
(sense) and 5’-TTGGCTCCAGAAAATTCACC-3’ (anti-sense) for
TRX (17), and 5’-TGTTGCCATCAATGACCCCTT-3’ (sense) and
5’-CTCCACGACGTACTCAGCG-3’ (anti-sense) for GAPDH (18). 
Preparation of TRX-specific mRNA. To prepare TRX-specific
mRNA for cell-free protein synthesis, the first-strand cDNA
synthesized was amplified with a Takara PCR Amplification kit
using specific primers for TRX in a final volume of 30 μl. The PCR
conditions were as follows: 5 min at 94˚C, followed by 30 cycles
of 20 s at 94˚C, 30 s at 58˚C, and 30 s at 72˚C. After measuring
mRNA contents, samples were stored at –80˚C until used.
Cell-free protein synthesis. Cell-free protein synthesis was cell-free
protein synthesis core kits (Toyobo Co., Ltd., Osaka, Japan). The
reaction mixture consisted of 2.0 μl of reaction buffer, 1.7 μl of
creatine kinase (10 μg/ml), 1.0 μl of ribonuclease inhibitor 
(40 U/ml), 10.0 μl of wheat germ extract, 33.5 μl of specific mRNA
(0.4 μg/μl) and distilled water containing different concentrations
of CAM to a final volume of 50.0 μl. The reaction mixture (50 μl)
was then introduced into each well of 96-well plates that contained
250 μl of reaction buffer. The plates were incubated at 26˚C for 
24 h and the solutions were stored at –40˚C until use.
Assay for TRX. TRX levels in culture supernatants and protein
synthesis solution were examined by the commercially available
TRX enzyme-linked immunosorbent assay (ELISA) test kits
(BioVendor Lab. Med. Inc., Brno, Czech Republic), according to
the manufacturer’s recommendations. The minimum detectable level
of this kit was 2.13 ng/ml.
Statistical analysis. The statistical significance between control and
experimental groups was examined by analysis of variance
(ANOVA) followed by the Dunette’s multiple comparison test. The
level of significance was considered at a p-value of less than 0.05.
Results
Influence of H2O2 stimulation on TRX production from nasal
epithelial cells in vitro. The first experiments were
undertaken to examine whether H2O2 stimulation increased
TRX production from nasal epithelial cells and the optimal
concentration of H2O2 for stimulation. To do this, the cells
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were stimulated with different concentrations of H2O2 for 24 h,
and the TRX levels in culture supernatants were examined by
ELISA. As shown in Figure 1, stimulation of cells with H2O2
caused a significant increase in the ability of cells to produce
TRX. As little as 2.5 μM of H2O2 strongly stimulated TRX
production. Maximal production was obtained with 25.0 to 
75.0 μM of H2O2, and 100 μM was inhibitory (Figure 1). 
Influence of macrolide antibiotics on H2O2-induced TRX
production from nasal epithelial cells in vitro. The second set
of experiments was designed to examine the influence of
macrolide antibiotics on TRX production from nasal
epithelial cells after H2O2 stimulation. The cells were
stimulated with 50 μM H2O2 in the presence of either CAM
or JM for 24 h. TRX levels in culture supernatants were
examined by ELISA. As shown in Figure 2, treatment of cells
with CAM at concentrations of both 0.2 μg/ml and 0.4 μg/ml
scarcely affected the ability of cells to produce TRX; TRX
levels in culture supernatants were nearly identical to those
detected in the control. CAM at 0.5 μg/ml or more
significantly increased the TRX levels in culture supernatants,
as compared with that in the control. On the other hand, JM
did not increase TRX production from nasal epithelial cells
in response to H2O2 stimulation even when 10.0 μg/ml of the
agent was used for treatment. 
Influence of CAM on TRX mRNA expression in nasal
epithelial cells in vitro. The third set of experiments was
undertaken to examine the influence of CAM on TRX mRNA
expression in nasal epithelial cells in vitro. As shown in
Figure 3, stimulation of cells with H2O2 caused significant
increase in TRX mRNA level, as compared with the non-
stimulated control. On the other hand, the addition of CAM
at 0.5 μg/ml but not 0.2 μg/ml caused a significant decrease
in TRX mRNA expression, which was increased by H2O2
stimulation. 
Influence of CAM on cell-free protein synthesis. The final set
of experiments was designed to examine the influence of
CAM on TRX production in cell-free protein systems. As
shown in Figure 4, the addition of CAM at 0.1 μg/ml and 
0.2 μg/ml into cell-free protein systems did not increase
TRX synthesis; TRX level in the solutions were nearly
identical (p>0.05; not significant) to those observed in the
control. On the other hand, CAM at more than 0.5 μg/ml
significantly increased the ability of wheat germ extract to
produce specific protein as compared with the control.
Discussion
Low-dose and long-term administration of macrolide
antibiotics, also called macrolide therapy, is effective in the
treatment of DPB, CS and CF (4). In addition to these airway
inflammatory diseases, several types of skin diseases
characterized by inflammatory disorders are also reported to
be susceptible to the macrolide therapy (19, 20). There is
considerable evidence to suggest that the inhibitory action of
macrolides on the chemotaxis and activation of inflammatory
cells such as neutrophils, which are the most important
effector cells in the development of chronic airway
inflammatory diseases, may account for the clinical efficacy
of macrolides in inflammatory diseases (4). 
Oxygen-consuming organisms obtain energy through
cellular respiration, which is the transformation of
carbohydrates and oxygen into carbon dioxide and water.
Up to two percent of the oxygen used in this system is
transformed into superoxide, a free radical that is toxic to
cells. Furthermore, free radicals also produced by
phagocytic cells such as macrophages and granulocytes,
which are cells essential to the development of airway
inflammatory diseases, and function in the intracellular
killing of bacteria. Because free radicals are necessary for
life, the body has a number of mechanisms to minimize
free-radical-induced damage and to repair damage that
occurs, such as via several types of enzymes and
endogenous proteins. Among these, TRX attracts attention
as being not only an important antioxidative factor (8-10)
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Figure 1. Influence of H2O2 on thioredoxin (TRX) production from nasal
epithelial cells in vitro. Nasal epithelial cells (5×105 cells) were
stimulated with different concentrations of H2O2. After 24 h, TRX levels
in culture supernatants were examined by ELISA. The data are
expressed as the mean±SE of five cultures from different subjects.
*Significant at p<0.05 vs. 0 μM H2O2; **p>0.05 vs. 12.5 μM H2O2.
but also a protective factor in the development of various
inflammatory diseases (12-15). However, there is little
evidence showing the influence of macrolide antibiotics on
TRX. The present study clearly demonstrates that CAM
increases the ability of nasal epithelial cells to produce TRX
in response to H2O2 stimulation, when the cells were treated
with the agent at more than 0.5 μg/ml, which is a quite low
level compared with therapeutic blood levels (1.03±0.16
μg/ml) (21). On the other hand, JM, which is ineffective in
the treatment of DPB and CS (4), did not increase TRX
levels in the culture supernatants even when the cells were
treated with 10.0 μg/ml. TRX, a well-characterized protein
with a highly conserved active site, is reported to play a
variety of redox-related roles in organisms from bacteria to
Man (12, 13). Intracellular TRX, together with
peroxiredoxin, plays essential roles in the scavenging of free
radicals and the regulation of redox-sensitive transcription
factors such as nuclear factor (NF)-κB and activator protein
(AP)-1 (13). In addition to intracellular functions, TRX has
been shown to inhibit neutrophil chemotaxis induced by
lipopolysaccharide (LPS) and chemokine stimulation (13).
It is also reported that TRX directly blocks the adhesion of
LPS-stimulated neutrophils on endothelial cells in vitro (13).
Furthermore, TRX inhibits the down-regulation of L-selectin
precursor (CD62L) expression on neutrophils after LPS
stimulation via the suppression of p38 mitogen-activated
protein kinase phosphorylation (13), suggesting that TRX
exerts a suppressive effect on neutrophil activation. In the
development of airway inflammatory diseases,
administration of TRX into mice for three days prevented
lung injury induced by exposure by cigarette smoking
through the suppression of neutrophil influx (22). Moreover,
although chronic exposure by cigarette smoking is reported
to cause pulmonary emphysema in normal mice
accompanying prominent infiltration of macrophages and
neutrophils into the lung, TRX-transgenic mice, which
produce much higher levels of human TRX in response to
inflammatory stimulation, significantly prevented the
development of these pathological changes (22). Taken
together, the present data show that the enhancement of
TRX production by nasal epithelial cells may be interpreted
as part of the therapeutic mode of action of 14-membered
macrolides in chronic airway inflammatory diseases. 
Forkhead transcription factor-3 (FOXO3) is reported to be
an essential transcription factor involved in the up-regulation
of TRX mRNA expression (17). It is also reported that AMP-
activated protein kinase (AMPK) plays a pivotal role in
phosphorylation of FOXO3 (23), which is responsible for the
promotion of TRX transcription in nuclei, indicating that the
AMPK-FOXO3 pathway is essential for TRX mRNA
expression (17, 23). Together with these reports, the present
results showing the inhibitory effect of CAM on TRX mRNA
expression may be, in part, due to the suppressive effect of
the agent on AMPK-FOXO3 pathway activation. This
speculation may be supported by the observation that 14-
membered macrolide antibiotics, including CAM, exert a
suppressive effect on the activation of transcription factors
such as NF-κB and AP-1 through the inhibition of activation
of MAPKs (3). On the other hand, the present results clearly
show that treatment of nasal epithelial cells with CAM
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Figure 2. Influence of macrolide antibiotics on thioredoxin (TRX) production from nasal epithelial cells induced by H2O2 stimulation in vitro. Nasal
epithelial cells (5×105 cells) were stimulated with 50 μM H2O2 in the presence of clarithromycin (CAM) or josamycin (JM) for 24 h. TRX levels in
culture supernatants were examined by ELISA. The data are expressed as the mean±SE of cells from five different subjects. A: CAM; B: JM;
*Significant at p<0.05 vs. H2O2 alone. 
caused an increase in TRX protein production in spite of the
suppression of its mRNA expression induced by H2O2
stimulation. The reasons for this discrepancy are not clear at
present. The process of protein synthesis in cells requires two
different steps: in the first step, transcription, mRNA is
synthesized from DNA in the nucleus. mRNA formed then
comes out through the nuclear membrane into the cytoplasm
where it binds to mRNA-binding sites on ribosomes and
starts protein synthesis translocation. The final experiments,
therefore, were undertaken to examine whether pre-treatment
of nasal epithelial cells with CAM could increase the
translocation activity of TRX mRNA. Cell-free protein
synthesis assay revealed that the addition of CAM at more
than 0.5 μg/ml could increase TRX synthesis. These results
strongly suggest that there is the possibility that CAM could
increase the translation of TRX mRNA, resulting in an
increase of TRX levels in culture supernatants. Further
experiments are required to clarify this point. 
The present results strongly suggest that macrolide therapy
causes an increase in the ability of airway cells, especially
epithelial cells, to produce TRX, explaining the favorable
modification of clinical symptoms of chronic airway
inflammatory diseases (e.g. DPB and CS) through the
suppression of both neutrophil influx and oxidative stress
responses in the area of inflammation.
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